Trichostatin A-mediated upregulation of p21WAF1 contributes to osteoclast apoptosis

被引:42
作者
Yi, TacGhee
Baek, Jeong-Hwa
Kim, Hye-Jin
Choi, Mi-Hye
Seo, Sang-Beom
Ryoo, Hyun-Mo
Kim, Gwan-Shik
Woo, Kyung Mi [1 ]
机构
[1] Seoul Natl Univ, Dept Cell & Dev Biol, Dent Res Inst, Seoul 110749, South Korea
[2] Seoul Natl Univ, BK21 Program, Sch Dent, Seoul 110749, South Korea
[3] Chung Ang Univ, Coll Nat Sci, Dept Life Sci, Seoul 156756, South Korea
关键词
apoptosis; CDKN1A protein; mouse; cyclin-dependent kinase inhibitor p21; histone deacetylases; osteoclasts; RNA interference; trichostatin A;
D O I
10.1038/emm.2007.24
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Histone deacetylase inhibitors (HDIs), a new class of anti-cancer agents, have been reported to suppress formation of osteoclast precursors and their fusion into multinucleated cells. However, little is known about the effect of HDIs on mature osteoclasts, which may have significance for their therapeutic use. Here, we demonstrate a novel action of HDIs on osteoclast apoptosis. Primary multinucleated mature osteoclasts were prepared from mouse bone marrow cells. Treatment of osteoclasts with the HDI trichostatin A (TSA) caused apoptosis, as confirmed by annexin V staining and caspase activation. TSA caused the upregulation of p21(WAF1) in osteoclasts. To understand the role of p21(WAF1) upregulation in TSA-treated osteoclasts, shRNA against p21(WAF1)-containing lentivirus was introduced into osteoclasts. The suppression of p21(WAF1) decreased TSA-directed osteoclast apoptosis. Collectively, our results pro vide evidence that TSA causes osteoclast apoptosis, which involves, in part, TSA-induced upregulation of p21(WAF1), and strongly supports HDIs as potential therapeutic agents for excessive bone resorption.
引用
收藏
页码:213 / 221
页数:9
相关论文
共 23 条
[1]   Osteoclast differentiation and activation [J].
Boyle, WJ ;
Simonet, WS ;
Lacey, DL .
NATURE, 2003, 423 (6937) :337-342
[2]  
Burgess AJ, 2001, MOL PHARMACOL, V60, P828
[3]   Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21waf1 [J].
Chopin, V ;
Slomianny, C ;
Hondermarck, H ;
Le Bourhis, X .
EXPERIMENTAL CELL RESEARCH, 2004, 298 (02) :560-573
[4]   New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? [J].
Coqueret, O .
TRENDS IN CELL BIOLOGY, 2003, 13 (02) :65-70
[5]  
Fuller K, 2000, J CELL SCI, V113, P2445
[6]  
Gartel AL, 2002, MOL CANCER THER, V1, P639
[7]   Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1 [J].
Gui, CY ;
Ngo, L ;
Xu, WS ;
Richon, VM ;
Marks, PA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (05) :1241-1246
[8]   Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta [J].
Hughes, DE ;
Dai, AH ;
Tiffee, JC ;
Li, HH ;
Mundy, GR ;
Boyce, BF .
NATURE MEDICINE, 1996, 2 (10) :1132-1136
[9]   Bone morphogenetic protein-2 stimulates Runx2 acetylation [J].
Jeon, Eun-Joo ;
Lee, Kwang-Youl ;
Choi, Nam-Sook ;
Lee, Mi-Hye ;
Kim, Hyun-Nam ;
Jin, Yun-Hye ;
Ryoo, Hyun-Mo ;
Choi, Je-Yong ;
Yoshida, Minoru ;
Nishino, Norikazu ;
Oh, Byung-Chul ;
Lee, Kyeong-Sook ;
Lee, Yong Hee ;
Bae, Suk-Chul .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (24) :16502-16511
[10]   Antioxidant α-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-κB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-κB ligand and tumor necrosis factor-α [J].
Kim, Hyon Jong ;
Chang, Eun-Ju ;
Kim, Hyun-Man ;
Lee, Seung Bok ;
Kim, Hyun-Duck ;
Kim, Ghi Su ;
Kim, Hong-Hee .
FREE RADICAL BIOLOGY AND MEDICINE, 2006, 40 (09) :1483-1493